ABIO vs. ACHV, TKNO, VNRX, ICCC, AWH, OCX, TRIB, CDIO, BMRA, and MYMD
Should you be buying ARCA biopharma stock or one of its competitors? The main competitors of ARCA biopharma include Achieve Life Sciences (ACHV), Alpha Teknova (TKNO), VolitionRx (VNRX), ImmuCell (ICCC), Aspira Women's Health (AWH), OncoCyte (OCX), Trinity Biotech (TRIB), Cardio Diagnostics (CDIO), Biomerica (BMRA), and MyMD Pharmaceuticals (MYMD). These companies are all part of the "diagnostic substances" industry.
ARCA biopharma (NASDAQ:ABIO) and Achieve Life Sciences (NASDAQ:ACHV) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, community ranking, institutional ownership, profitability and media sentiment.
In the previous week, ARCA biopharma had 1 more articles in the media than Achieve Life Sciences. MarketBeat recorded 1 mentions for ARCA biopharma and 0 mentions for Achieve Life Sciences. ARCA biopharma's average media sentiment score of 0.00 equaled Achieve Life Sciences'average media sentiment score.
ARCA biopharma's return on equity of -16.08% beat Achieve Life Sciences' return on equity.
Achieve Life Sciences has a consensus target price of $14.00, suggesting a potential upside of 164.15%. Given Achieve Life Sciences' higher possible upside, analysts clearly believe Achieve Life Sciences is more favorable than ARCA biopharma.
56.4% of ARCA biopharma shares are held by institutional investors. Comparatively, 33.5% of Achieve Life Sciences shares are held by institutional investors. 30.9% of ARCA biopharma shares are held by company insiders. Comparatively, 2.0% of Achieve Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
ARCA biopharma has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500. Comparatively, Achieve Life Sciences has a beta of 1.34, meaning that its share price is 34% more volatile than the S&P 500.
ARCA biopharma is trading at a lower price-to-earnings ratio than Achieve Life Sciences, indicating that it is currently the more affordable of the two stocks.
Achieve Life Sciences received 207 more outperform votes than ARCA biopharma when rated by MarketBeat users. Likewise, 70.21% of users gave Achieve Life Sciences an outperform vote while only 41.98% of users gave ARCA biopharma an outperform vote.
Summary
ARCA biopharma beats Achieve Life Sciences on 7 of the 13 factors compared between the two stocks.
Get ARCA biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for ABIO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ABIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ARCA biopharma Competitors List
Related Companies and Tools
